Following a 7.94% increase during the regular session, when the stock finished at $13.18, Nurix Therapeutics, Inc. (NASDAQ: NRIX) showed great momentum in the extended trading session, rising 17.37% to $15.47.
The company’s Q2 2025 financial results, which showed notable revenue growth and milestone accomplishments throughout its medicinal portfolio and partnerships, preceded the strong increase.
Partnerships Drive Revenue Growth
Nurix recorded $44.1 million in revenue for the fiscal quarter that concluded on May 31, 2025, a significant rise over the $12.1 million generated during the same period the previous year. A $30 million licensing payment from Sanofi as a result of two license agreements being extended and a $5 million milestone payment from Gilead were primarily responsible for this rise.
The firm reported a net loss of $43.5 million, or ($0.52) per share, despite the upward sales trend. This was a slight improvement above the $44.5 million loss, or ($0.71) per share, in the previous year.
Clinical Development and Regulatory Successes
Several clinical and regulatory developments occurred throughout the quarter. Sanofi extended its license for the STAT6 program after Nurix achieved significant milestones, which resulted in an extra $15 million payment. With this extension, the Sanofi collaboration’s total payouts reached $127 million, with a further $465 million in possible future milestones.
Gilead and Nurix also said that the FDA has approved the IND application for GS-6791 (NX-0479), a first-of-its-kind oral IRAK4 degrader intended to treat inflammatory and autoimmune disorders.
Promising Clinical Data and EMA Recognition
Nurix provided strong Phase 1 data for bexobrutideg (NX-5948) at EHA2025 and ICML-18. These data showed an objective response rate of 80.9% in patients with relapsed or refractory CLL, including a full response in a high-risk case.
Additionally, bexobrutideg was given orphan drug status (ODD) by the European Medicines Agency (EMA) for lymphoplasmacytic lymphoma, providing strategic regulatory advantages inside the EU.
Artificial Intelligence-Based Innovation
At the AACR Annual Meeting, Nurix also demonstrated their DEL-AI platform, which uses a unique DNA-encoded library-based foundation model to speed up the discovery of new binders for challenging medicinal targets.
Nurix’s growing portfolio of degraders and strategic partnerships highlight the company’s leadership in immunology and cancer therapeutic innovation as it enters a critical phase.
